MedPharm

The long-awaited hearing to discuss cannabis rescheduling will begin on January 21, 2025, marking a significant moment in the ongoing debate over cannabis regulation. As Business of Cannabis reported, the six-week hearing will continue until March 6, 2025, but its outcome remains uncertain due to...

A DEA administrative law judge has denied MedPharm's motion to participate in the December 2 marijuana rescheduling hearing, deferring to DEA Administrator Anne Milgram's authority. MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of...

MedPharm Research’s proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled “Isolation and pharmacological evaluation of phytocannabinoids for Alzheimer’s disease,” has been...

Earlier this week, Medicine Man Technologies Inc (OTC: MDCL) announced its ninth acquisition since the passing of the HB19-1090, Publicly Licensed Marijuana Companies bill, in Colorado, in April. Over the course of 2019, Medicine Man Technologies has announced the following (pending) acquisitions...